234 related articles for article (PubMed ID: 33621416)
1. Selective Inhibition of the Hsp90α Isoform.
Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
Khandelwal A; Kent CN; Balch M; Peng S; Mishra SJ; Deng J; Day VW; Liu W; Subramanian C; Cohen M; Holzbeierlein JM; Matts R; Blagg BSJ
Nat Commun; 2018 Jan; 9(1):425. PubMed ID: 29382832
[TBL] [Abstract][Full Text] [Related]
3. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
Mak OW; Chand R; Reynisson J; Leung IKH
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
Chaudhury S; Narasimharao Meka P; Banerjee M; Kent CN; Blagg BSJ
Chemistry; 2021 Oct; 27(59):14747-14764. PubMed ID: 34449940
[TBL] [Abstract][Full Text] [Related]
5. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
Mishra SJ; Liu W; Beebe K; Banerjee M; Kent CN; Munthali V; Koren J; Taylor JA; Neckers LM; Holzbeierlein J; Blagg BSJ
J Med Chem; 2021 Feb; 64(3):1545-1557. PubMed ID: 33428418
[TBL] [Abstract][Full Text] [Related]
6. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
Ernst JT; Liu M; Zuccola H; Neubert T; Beaumont K; Turnbull A; Kallel A; Vought B; Stamos D
Bioorg Med Chem Lett; 2014 Jan; 24(1):204-8. PubMed ID: 24332488
[TBL] [Abstract][Full Text] [Related]
7. Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.
Yu J; Zhang C; Song C
Eur J Med Chem; 2022 Aug; 238():114516. PubMed ID: 35691175
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
10. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
Bhat R; Tummalapalli SR; Rotella DP
J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
[TBL] [Abstract][Full Text] [Related]
11. Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.
Dernovšek J; Tomašič T
Pharmacol Ther; 2023 May; 245():108396. PubMed ID: 37001734
[TBL] [Abstract][Full Text] [Related]
12. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Evaluation of Simplified Cruentaren A Analogues.
Dou X; Patel BA; D'Amico T; Subramanian C; Cousineau E; Yi Y; Cohen M; Blagg BSJ
J Org Chem; 2022 Aug; 87(15):9940-9956. PubMed ID: 35894845
[TBL] [Abstract][Full Text] [Related]
14. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
15. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
[TBL] [Abstract][Full Text] [Related]
16. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells.
Ghosh S; Shinogle HE; Garg G; Vielhauer GA; Holzbeierlein JM; Dobrowsky RT; Blagg BS
ACS Chem Biol; 2015 Feb; 10(2):577-90. PubMed ID: 25402753
[TBL] [Abstract][Full Text] [Related]
18. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
19. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
20. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
